The Current State of Hormonal Therapy for Prostate Cancer

@article{Hellerstedt2002TheCS,
  title={The Current State of Hormonal Therapy for Prostate Cancer},
  author={Beth A. Hellerstedt and Kenneth J. Pienta},
  journal={CA: A Cancer Journal for Clinicians},
  year={2002},
  volume={52}
}
Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics. 

Paper Mentions

Interventional Clinical Trial
To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer  
ConditionsProstate Adenocarcinoma
InterventionDrug
Interventional Clinical Trial
This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients… Expand
ConditionsAdenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, (+1 more)
InterventionDrug
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.
TLDR
The rationale behind the use of novel agents targeting the androgen receptor and its signaling pathways in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer are described. Expand
Hormonotherapy of advanced prostate cancer.
  • P. Pronzato, M. Rondini
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
TLDR
Androgen ablation remains the mainstay of treatment for advanced stages, while Docetaxel based chemotherapy is becoming the standard in hormonorefractory tumors and targeted therapies are approaching. Expand
The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer
TLDR
A variety of radiotherapeutic options exist for palliation in the setting of castrate-resistant prostate cancer, including both external beam radiotherapy and radiopharmaceuticals, which are focused on in this article. Expand
New pharmacological treatments for prostate cancer
In this article, a summary of new drugs available for patients with prostate cancer, such as degarelix, abiraterone acetate, sipuleucel-T, bone-targeted therapies, and chemotherapeutic agents, andExpand
The truth is out there: an overall perspective on androgen deprivation.
TLDR
New combinations and treatment settings show promise for improving outcomes and decreasing toxicity in androgen deprivation therapy. Expand
Current Pharmacological Treatment Options for Prostate Cancer
TLDR
The current pharmacological treatment options in the management of prostate cancer are reviewed to lead to earlier diagnosis and more effective management. Expand
Risk of new‐onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population
TLDR
The risk of new‐onset diabetes mellitus (DM) after ADT for prostate cancer in the Asian population is investigated to investigate the associations of androgen deprivation therapy with its adverse events. Expand
Survival outcomes in men receiving androgen‐deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20‐year single‐centre experience
To evaluate the overall survival (OS) and disease‐specific survival (DSS) in men receiving primary androgen‐deprivation therapy (PADT) or salvage medical ADT (SADT) for prostate cancer.
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer
TLDR
By providing clinicians with a greater awareness of the estrogen deficiency induced adverse effects from ADT, they can proactively intervene on the physical and psychological impact these effects have on patients. Expand
Cryoablative response of prostate cancer cells is influenced by androgen receptor expression
To investigate in prostate cancer cells the consequences of androgen‐insensitivity (AI) development on the cellular and molecular responses to freezing, as a challenge in prostate cancer treatmentExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
Trends in the utilization of androgen‐deprivation therapy for patients with prostate carcinoma suggest an effect on mortality
After a surge in the incidence of prostate carcinoma in the early 1990s, diminishing rates of mortality became apparent in 1993. This decrease in mortality is unlikely to be explained entirely byExpand
Side effects of endocrine treatment and their mechanisms: Castration, antiandrogens, and estrogens
TLDR
This paper is a survey of the most important early side effects of the different modes of endocrine treatment, their etiology, and possible ways to avoid or treat them. Expand
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences *
The meta‐analysis of maximal androgen blockade (MAB) concluded that there is no survival advantage of MAB over castration alone. However, the results from the largest trials yield conflicting results.
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma
TLDR
The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities in men with disseminated prostate carcinoma treated with combined androgen blockade prior to and after 6 months of intermittent cyclic etidronate therapy. Expand
Intermittent Androgen Blockade in Prostate Cancer: Rationale and Clinical Experience
TLDR
Experimental and preclinical studies concerning intermittent androgen blockade are reviewed and it is found that through the cycling of reversible androgen suppression, there appears to be recovery of apoptosis and subsequent slower progression to an androgen–independent state. Expand
Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
TLDR
Nine men with histologically confirmed stage D cancer of the prostate were evaluated with serial serum testosterone levels after being treated with bilateral orchiectomy or intravenous estrogen and both forms of therapy are safe, produce a clinically effective response and offer advantages for patients with advanced prostatic cancer. Expand
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
TLDR
The role of ADT in patients with clinically localized and recurrent prostate cancer, whether it is delivered in a continuous or intermittent fashion, must be determined in randomized, prospective trials. Expand
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
TLDR
Although median follow-up is short, triple androgen blockade therapy followed by finasteride maintenance appears to be a promising alternative for the management of patients with clinically localized or locally advanced prostate cancer. Expand
Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
TLDR
IAD appears to be a viable treatment option in selected patients with clinically localized prostate cancer, however, the durability and advantage of IAD, if any, over continuous therapy is unknown at present. Expand
Chapter 46 – Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy
TLDR
Although the studies are preliminary, combination therapy deserves further exploration, as it is suggested that AIPC can be responsive to novel chemotherapeutic agents. Expand
...
1
2
3
4
5
...